Description: Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron (R), Sylatron (R), Macugen (R) and CIMZIA (R). The primary source of the Company's royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc.
Home Page: www.enzon.com
20 Commerce Drive
Cranford,
NJ
07016
United States
Phone:
732 980 4500
Officers
| Name | Title |
|---|---|
| Mr. Richard L. Feinstein | CEO, CFO & Company Sec. |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4053 |
| Price-to-Sales TTM: | 669.3645 |
| IPO Date: | 1984-02-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |